Last Price$2.95.0%
Market Cap$2,541.3M
(99.7%)
Peers median - 4.2%
(28,634,171.0%)
Peers median - 14.9%
72,288.9%
Peers median - 46.8%
(1.3%)
Peers median - 9.3%
Competing with HSCS
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$2,541.3M | 5.4 | $337.2 11,448.4% undervalued | (75.8%) | $14.7K | ($4,209.2M) | (99.7%) | (28,634,171.0%) | (245.6%) | (1.3%) | 72,288.9% | |
$231.4B | 7.0 | $178.1 34.3% undervalued | 12.6% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$140.4B | 6.8 | $36.4 61.9% overvalued | 44.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$139.3B | 6.5 | $300.2 17.8% overvalued | 3.7% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 10.4% | 65.9% | |
$119.7B | 6.4 | $117.2 25.6% undervalued | 12.8% | $33.2B | $5,467.0M | 2.7% | 16.5% | 62.9% | 7.4% | 53.6% | |
$40.4B | 6.2 | $54.2 20.8% overvalued | (24.7%) | $5,724.3M | $289.9M | (4.7%) | 5.1% | 78.4% | 21.6% | 7.0% | |
$28.0B | 7.3 | $39.4 43.9% overvalued | (47.2%) | $4,033.0M | $630.7M | 11.3% | 15.6% | 60.4% | 21.7% | 120.3% | |
$24.6B | 5.3 | $69.4 159.4% undervalued | 29.2% | €18.0B | €1,145.0M | (0.8%) | 6.4% | 43.1% | (4.2%) | 63.4% | |
$22.6B | 6.4 | $194.8 14.6% overvalued | (1.5%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 35.6% | |
$21.8B | 5.8 | $178.8 66.6% undervalued | (15.4%) | $7,678.6M | $1,132.4M | 3.8% | 14.7% | 66.0% | 6.3% | 43.0% | |
$17.2B | 7.9 | $104.8 57.3% overvalued | 35.4% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 26.9% | 6.9% |
Compare HSCS Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Heart Test Laboratories, Inc.HSCS
94,751.4x
261.2%
(99.7%)
(35,511.9%)
Median Peer Set
6.1x
4.2%
59.2%
12.5%
Abbott LaboratoriesABT
5.7x
4.6%
134.5%
31.9%
Boston Scientific CorporationBSX
9.0x
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
6.9x
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
6.5x
(9.4%)
202.2%
76.7%
Medtronic plcMDT
4.2x
3.6%
(2.1%)
11.4%
Koninklijke Philips N.V.PHG
1.5x
(0.8%)
122.5%
(3.9%)
Insulet CorporationPODD
8.6x
22.1%
101.7%
20.2%
STERIS plcSTE
4.6x
3.6%
257.9%
7.4%
Stryker CorporationSYK
6.6x
10.2%
(5.8%)
13.2%
Zimmer Biomet Holdings, Inc.ZBH
3.6x
3.8%
(9.4%)
11.8%
Compare HSCS Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Heart Test Laboratories, Inc. (HSCS) revenue growth compare to peers and the industry?
Heart Test Laboratories, Inc. (HSCS) revenue growth is (99.7%), compared to the peers' median of 4.2%.
2. How does Heart Test Laboratories, Inc. (HSCS) Free Cash Flow (FCF) margin compare to peers and the industry?
Heart Test Laboratories, Inc. (HSCS) FCF margin is (28,634,171.0%), compared to the peers' median of 14.9%.
3. How does Heart Test Laboratories, Inc. (HSCS) Total Debt to Equity ratio compare to peers and the industry?
Heart Test Laboratories, Inc. (HSCS) Total Debt to Equity ratio is 72,288.9%, compared to the peers' median of 46.8%.
4. How does Heart Test Laboratories, Inc. (HSCS) ROIC (Return on Invested Capital) compare to peers and the industry?
Heart Test Laboratories, Inc. (HSCS) ROIC is (1.3%), compared to the peers' median of 9.3%.